Lightnews — Scholar-powered news

VJHemOnc

@vjhemonc.bsky.social

390 followers 50 following 470 posts

The Video Journal of Hematology & Hematological Oncology is dedicated to providing up-to-date information & international expertise🩸🎥 🗞️ #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #CLLsm #AMLsm #Leukemia #Lymphoma #Myeloma

Posts Media Videos Starter Packs

Pinned

VJHemOnc @vjhemonc.bsky.social · Nov 18

Welcome!👋🧡

We are a global, open access, expert-led video journal bringing healthcare professionals trustworthy, cutting-edge updates in #HemOnc🔦

🩸Disease areas www.vjhemonc.com/subjects/#all

🎧VJHemOnc Podcast www.vjhemonc.com/podcasts/

📩VJHemOnc Newsletter www.vjhemonc.com/newsletter/

1 4

VJHemOnc @vjhemonc.bsky.social · 12h

Thank you to Claudio Cerchione for stopping by at #IMS25 to share insight into the use of anti-CD38–based quadruplet regimens for patients with transplant-ineligible #MultipleMyeloma.🩸

Check out the interview here:

👉 buff.ly/jVocJUD 👈

#MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 1d

We recently spoke with Pankit Vachhani, who discussed the potential of MDM2 inhibitors for treating MPNs, outlining the encouraging results observed to date with the MDM2 inhibitor navtemadlin.

Click here to watch:

🎥 buff.ly/cBf3tFe

#MPNsm #HemOnc #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 2d

PNH is a rare acquired clonal hematopoietic stem cell disorder.🩸

Learn about the biology, diagnosis, & treatment of this non-malignant disease in our new article, featuring interviews with leading experts Austin Kulasekararaj, Catherine Flynn, & Jens Panse!

Click here:
🔗 buff.ly/WRSulMR

#MedSky

VJHemOnc @vjhemonc.bsky.social · 2d

Want to learn about the potential value of circulating tumor DNA in Hodgkin #lymphoma? 🧬🩸

Make sure to watch our recent interview with Jonathan Friedberg of @wilmotcancer.bsky.social here:

🎥 👉 buff.ly/fZ3K2nD

#HodgkinLymphoma #LYMsm #HemOnc #SOHO2025 #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 3d

At #iwAL25, leading experts Mark Levis, Eunice Wang, and Sanam Loghavi participated in a thought-provoking debate about the value and utility of MRD in the management of adults with newly diagnosed AML.🩸

Watch it here: 👉 buff.ly/XfMfsmQ

#AMLsm #Leusm #MRD #HemOnc #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 4d

At #SOHO2025, Sarah Tasian shared insights into the management of Ph-like ALL, highlighting the move toward an individualized, precision medicine approach.

Watch the interview here:

👉 buff.ly/E837gwk 👈

#ALLsm #Leusm #Leukemia #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 5d

Thank you to the lovely Hang Quach of @unimelb.bsky.social for speaking with us at #IMS25 to share results from part one of the Phase I/II DREAMM-20 trial investigating belantamab in pts with R/R #MultipleMyeloma.🩸

Watch now:

🎥 buff.ly/zBD1MpN

#MMsm #Myeloma #CTSM #TrialUpdate #ImmunoOnc #HemOnc

VJHemOnc @vjhemonc.bsky.social · 5d

In an interview from #SOHO2025, Matteo Della Porta shares insights into the significance of anemia in MDS & MPNs, highlighting the need to develop effective therapies for this clinical feature.

Click to watch:

👉 buff.ly/rXyC3pf 👈

#MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 6d

It's always a pleasure to catch up with Hermann Einsele!😊

At #IMS25, Prof. Einsele outlined ongoing trials in #CARTCell therapy for #MultipleMyeloma.💉🩸

Click here to watch the interview:

👉 buff.ly/Bc1gG2R 👈

#CTSM #ImmunoOnc #MMsm #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

VJHemOnc @vjhemonc.bsky.social · 6d

How can clinicians identify patients with MPNs whose disease is in the accelerated or blast phase? 🩸

🎥 @anand-88-patel.bsky.social shares insight into this in an interview from the #MPNWorkshop2025:

👉 buff.ly/ygLFHa4 👈

#MPNsm #HemOnc #MedSky #HemeSky #BloodSky

1 4

VJHemOnc @vjhemonc.bsky.social · 7d

🎥 Jennifer Marvin-Peek of @mdanderson.bsky.social shares the results of a Phase I/II study evaluating an all-oral triplet regimen combining decitabine, venetoclax, & ivosidenib or enasidenib in IDH1-/IDH2-mutated AML:

👉 buff.ly/Z3WVJCU 👈

#SOHO2025 #AMLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc

VJHemOnc @vjhemonc.bsky.social · 7d

At #IMS25, we spoke with Gareth Morgan, who provided practical advice to support earlier recognition and diagnosis of #amyloidosis.🩸

Click here to watch:

👉 buff.ly/iPaNSjm 👈

@myeloma-society.bsky.social #HemOnc #BloodSky #HemeSky #MedSky

1 1

VJHemOnc @vjhemonc.bsky.social · 8d

Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸

Watch our interview with Britten Gordon from #iwCLL2025:

🎥 buff.ly/eKQamE2

#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky

VJHemOnc @vjhemonc.bsky.social · 8d

At #IMS25, we caught up with Xavier Leleu of to hear about the Phase III IRAKLIA trial investigating isatuximab administered subcutaneously via an on-body injector versus intravenously in patients with R/R #MultipleMyeloma:

🎥 buff.ly/T67u8VR

#MMsm #Myeloma #TrialUpdate @myeloma-society.bsky.social

VJHemOnc @vjhemonc.bsky.social · 9d

🎥 Ranjit Nair of @mdanderson.bsky.social shares the promising results of a Phase I study evaluating surovatamig (AZD0486), a CD19-targeting bispecific T-cell engager, in patients with R/R #NonHodgkinLymphoma:

🎥 👉 buff.ly/k5zLkkg

#SOHO2025 #LYMsm #Lymphoma #CTSM @societyofhemonc.bsky.social

VJHemOnc @vjhemonc.bsky.social · 9d

Want to hear the evidence supporting the use of MRD-guided treatment in #MultipleMyeloma? 🤔🩸

Check out our interview from #IMS25 with Noemi Puig:

🎥 buff.ly/CtaSWCC

#MMsm #Myeloma #mmMRD #HemOnc @myeloma-society.bsky.social

VJHemOnc @vjhemonc.bsky.social · 10d

In an interesting interview from #SOHO2025, David Swoboda discusses the development of a novel AI-driven virtual tumor board designed to improve diagnosis, prognosis, and treatment recommendations in MDS.

Watch here:

🎥 buff.ly/wrh0OvA

#MDSsm #HemOnc #AI #BloodSky #HemeSky #MedSky

VJHemOnc @vjhemonc.bsky.social · 11d

Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸

Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:

🎥 buff.ly/AnTQebz

#CARTCell #ImmunoOnc #CLLsm #Leusm

VJHemOnc @vjhemonc.bsky.social · 12d

Missed out on #iwCLL2025?🩸

Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:

👉 buff.ly/GBOkgBn 👈

#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc

VJHemOnc @vjhemonc.bsky.social · 12d

In an interview from #SOHO2025, Gloria Iacoboni shares insights into the importance of bridging & holding therapy in patients with aggressive B-cell #lymphoma, highlighting the need to differentiate between the two terms:

👉 buff.ly/PlcXlRs 👈

#LYMsm #CARTCell #ImmunOnc #HemOnc #BloodSky #HemeSky

VJHemOnc @vjhemonc.bsky.social · 13d

As part of #BloodCancerAwarenessMonth, we're bringing you a special podcast series!

Our most recent episode features @rahulbanerjeemd.bsky.social, who shares expert insights into the definition & complexities of financial & time toxicity in #myeloma.

🎧 buff.ly/GNUBCFz

#MMsm #BMTsm #HemOnc

VJHemOnc @vjhemonc.bsky.social · 13d

🎥 @mhairicopland.bsky.social of @uofglasgow.bsky.social comments on the challenges of co-targeting in CML, highlighting the need to balance efficacy with minimizing additional side effects, particularly in patients who have achieved remission:

👉 buff.ly/eSCKsvx 👈

#SOHO2025 #CMLsm #Leusm #HemOnc

VJHemOnc @vjhemonc.bsky.social · 14d

It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥

Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:

👉 buff.ly/aouDK9h

#CLLsm

VJHemOnc @vjhemonc.bsky.social · 14d

It was a pleasure to catch up with David Sallman of @moffittnews.bsky.social at #SOHO2025 to hear about promising novel concepts being explored for the treatment of TP53-mutated.🩸

Want to learn more?

Click here to watch:
👉 buff.ly/2rbgMwQ 👈

#MDSsm #HemOnc #BloodSky @societyofhemonc.bsky.social

VJHemOnc @vjhemonc.bsky.social · 15d

🎙️ The VJHemOnc Podcast has been voted one of the Top 10 Hematology Podcasts of the Year by Million Podcasts 🏆

Stay ahead with the latest news, trial updates & debates in #Lymphoma, #Myeloma, #Leukemia & more.

EXPLORE NOW 👉 buff.ly/gv47n7q

#HemOnc #MMSM #Leusm #LYMsm #ImmunoOnc #BloodSky #HemeSky